Bioresorbable scaffolds in peripheral arterial disease

Expert Review of Cardiovascular Therapy

Volumn 12, Issue 4, 2014, Pages 443-450

  Kassimis, George ^a   Spiliopoulos, Stavros ^b   Katsanos, Konstantinos ^c   Tsetis, Dimitrios ^d   Krokidis, Miltiadis E ^e  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOY; COLLAGEN; POLYLACTIC ACID; POLYLACTIDE; PROTEOGLYCAN; STAINLESS STEEL;

BALLOON DILATATION; BARE METAL STENT; BIORESORBABLE SCAFFOLD; BLOOD VESSEL FUNCTION; DRUG ELUTING STENT; HEALTH CARE COST; HUMAN; IN-STENT RESTENOSIS; METAL STENT; NITINOL STENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; STENT; WOUND HEALING; BIODEGRADABLE IMPLANT; CORONARY RESTENOSIS; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; PERIPHERAL ARTERIAL DISEASE; TREATMENT OUTCOME;

EID: 84896952711     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2014.897226     Document Type: Review

References (51)

1. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007;370:937-48
2. Wentzel JJ, Whelan DM, van der Giessen WJ, et al. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech 2000;33:1287-95
3. Maier W, Windecker S, Kung A, et al. Exercise-induced coronary artery vasodilation is not impaired by stent placement. Circulation 2002;105:2373-7
4. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-42
5. Wilson GJ, Nakazawa G, Schwartz RS, et al. Comparison of inflammatory response after implantation of sirolimus - and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009;120:141-9
6. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-8
7. Patel N, Banning AP. Bioabsorbable scaffolds for the treatment of obstructive coronary artery disease: the next revolution in coronary intervention? Heart 2013;99: 1236-43
8. Katsanos K, Spiliopoulos S, Krokidis M, et al. Does below-the-knee placement of drug-eluting stents improve clinical outcomes? J Cardiovasc Surg (Torino) 2012;53(2):195-203
9. Katsanos K, Spiliopoulos S, Diamantopoulos A, et al. Systematic review of infrapopliteal drug-eluting stents: A meta-analysis of randomized controlled trials. Cardiovasc Intervent Radiol 2013; 36(3):645-58
10. Van Overhagen H, Spiliopoulos S, Tsetis D . Below-the-knee interventions. Cardiovasc Intervent Radiol 2013;36(2):302-11
11. Paraskevopoulos I, Spiliopoulos S, Davlouros P, et al. Evaluation of below-the-knee drug-eluting stents with frequency-domain optical coherence tomography: neointimal hyperplasia and neoatherosclerosis. J Endovasc Ther 2013; 20(1):80-93
12. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52: 1134-40
13. Garg S, Serruys P. Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Rev Cardiovasc Ther 2010;8:449-70
14. Palmerini T, Biondi-Zoccai G, Riva DD, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402
15. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115: 2435-41
16. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202
17. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009;120:391-9
18. Ramcharitar S, Garcia-Garcia HM, Nakazawa G, et al. Ultrasonic and pathological evidence of a neo-intimal plaque rupture in patients with bare metal stents. EuroIntervention 2007;3:290-1
19. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22
20. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008;372: 1163-73
21. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910
22. Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol 2006;18:70-4
23. Serruys P, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012;33: 16-25
24. Neil N. Stent fracture in the superficial femoral and proximal popliteal arteries: literature summary and economic impacts. Perspect Vasc Surg Endovasc Ther 2013; 25(1-2):20-7
25. Karnabatidis D, Katsanos K, Spiliopoulos S, et al. Incidence, anatomical location, and clinical significance of compressions and fractures in infrapopliteal balloonexpandable metal stents. J Endovasc Ther 2009;16(1):15-22
26. Okamura T, Serruys PW, Regar E. Three-dimensional visualization of intracoronary thrombus during stent implantation using the second generation, Fourier domain optical coherence tomography. Eur Heart J 2010;31:625
27. Patel N, Mechery A, Kassimis G, et al. Novel indication for bioabsorbable scaffold in metal allergy. EuroIntervention 2013. [Epub ahead of print]
28. Spuentrup E, Ruebben A, Mahnken A, et al. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation 2005;111: 1019-26
29. Eggebrecht H, Rodermann J, Hunold P, et al. Images in cardiovascular medicine. Novel magnetic resonance compatible coronary stent: the absorbable magnesium-alloy stent. Circulation 2005;112:e303-4
30. Gyongyosi M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000;35:1580-9
31. Gomez-Lara J, Brugaletta S, Diletti R, et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 2011;32:294-304
32. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010;3:1190-8
33. Stone G, Midei M, Newman W, et al. Randomized comparison of everolimuseluting and paclitaxel - eluting stents: two-year clinical follow-up from the clinical evaluation of the Xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery. Circulation 2009;119:680-6
34. Serruys PW, Ruygrok P, Neuzner J, et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2006;2:286-94
35. Tsuchida K, Piek JJ, Neumann F, et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (The SPIRIT FIRST Trial). EuroIntervention 2005;1:266-72
36. Radu M, Jorgensen E, Kelbaek H, et al. Strut apposition after coronary stent implantation visualised with optical coherence tomography. EuroIntervention 2010;6:86-93
37. Garg S, Serruys P. Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol 2009;57:537-65
38. Onuma Y, Piazza N, Ormiston JASP. Everolimus-eluting bioabsorbable stent - Abbot Vascular programme. EuroIntervention 2009;5(Suppl F):F98-102
39. Costopoulos C, Naganuma T, Latib A, Colombo A. Looking into the future with bioresorbable vascular scaffolds. Expert Rev Cardiovasc Ther 2013;11:1407-16
40. Deloose K. Bioresorbable vascular scaffolds: progress and potential. Endovascular Today; 2013
41. Bosiers M, Deloose K, Verbist J, Peeters P. First application of absorbable metal stents in the treatment of critical limb ischemia: 12-months results. Vasc Dis Manage 2006;2:86-91
42. Remedy, biodegradable peripheral stent registry. clinicaltrials.gov Identifier: NCT01420120. Available from: http:// clinicaltrials.gov/show/ NCT01420120
43. Goverde P, Vermassen F, Lansink W. Belgian REMEDY registry: use of bioabsorbable stents in superficial femoral artery lesions. Presented at EuroPCR, 20 - 23 May 2013; Paris, France
44. Bosiers M, Peeters P, D'Archambeau O, et al. AMS INSIGHT - absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol 2009;32(3):424-35
45. Biomedical bioresorbable scaffold system in the treatment of de novo superficial femoral artery (SFA) lesions (STANCE). ClinicalTrials.gov Identifier: NCT01403077. Available from: http:// clinicaltrials.gov/show/ NCT01403077
46. Iqbal J, Onuma Y, Ormiston J, et al. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J 2013. [Epub ahead of print]
47. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61(24): 2417-27
48. Krokidis M, Spiliopoulos S, Katsanos K, Sabharwal T. Peripheral applications of drug-coated balloons: past, present and future. Cardiovasc Intervent Radiol 2013; 36(2):281-91
49. Karnabatidis D, Katsanos K, Siablis D. Infrapopliteal stents: overview and unresolved issues. J Endovasc Ther 2009; 16(Suppl 1):I153-62
50. The ABSORB BTK (below the knee) Clinical Investigation. ClinicalTrials.gov Identifier: NCT01341340. Available from: http:// clinicaltrials.gov/show/NCT01341340
51. ESPRIT I: A clinical evaluation of the Abbott vascular ESPRIT BVS (bioresorbable vascular scaffold) system. ClinicalTrials.gov Identifier: NCT01468974. Available from: http://clinicaltrials.gov/show/NCT01468974